New insights into the association between AXIN2 148 C/T, 1365 C/T, and rs4791171 A/G variants and cancer risk

Table 1 Basic information for included studies of the correlation between AXIN2 148 C/T, 1365 C/T, and rs4791171 A/G variations and cancer risk

Author/year	Origin	Ethnicity	Source	Cancer	Method	Age range	Age range	Case	Control	Case			Control			HWE
148 C/T	Origin	Ethnicity	Source	Cancer	Method	Case	Control	Case	Control	TT	TC	CC	TT	TC	CC	HWE
Kanzaki 2006 [26]	Japan	Asian	PB	LC	PCR–RFLP	66.4 (mean)	NA	160	109	8	71	81	15	52	42	0.863
Kanzaki 2006 [26]	Japan	Asian	PB	HNC	PCR–RFLP	66.4 (mean)	NA	63	109	9	29	25	15	52	42	0.863
Kanzaki 2006 [26]	Japan	Asian	PB	CRC	PCR–RFLP	66.4 (mean)	NA	113	109	15	44	54	15	52	42	0.863
Gunes 2009 [19]	Turkey	Caucasian	PB	LC	PCR	59.22 ± 9.63	57.01 ± 7.89	100	100	8	47	45	16	52	32	0.501
Gunes 2010 [25]	Turkey	Caucasian	HB	AT	PCR	58.66 ± 8.04	57.01 ± 7.89	100	100	16	45	39	16	52	32	0.501
Pinarbasi 2011 [27]	Turkey	Caucasian	HB	PC	PCR	70.38 ± 7.78	68.55 ± 4.47	84	100	19	35	30	18	48	34	0.883
Naghibal 2012 [21]	Iran	Asian	HB	CRC	PCR–RFLP	NA	NA	110	179	19	57	34	26	98	55	0.096
Liu 2014 [28]	China	Asian	PB	LC	RT-PCR	57.78 ± 9.89	52.21 ± 10.56	498	533	47	216	235	67	255	211	0.457
Ma 2014 [22]	China	Asian	PB	PC	PCR	71.2 (mean)	70.4 (mean)	103	100	11	31	61	9	52	39	0.153
Mostowska 2014 [24]	Poland	Caucasian	HB	OC	PCR–RFLP	58.4 ± 9.7	57.4 ± 7.5	228	282	46	115	67	65	146	71	0.546
Yadav 2016 [23]	India	Asian	HB	GBC	Taqman	52.05 ± 10.06	43.2 ± 11.5	564	250	119	253	192	44	108	98	0.138
Liu 2016 [32]	China	Asian	HB	PTC	MassARRAY	45.13 ± 10.97	41.9 ± 10.22	53	50	2	24	27	4	29	17	0.084
Kim 2016 [31]	Korea	Asian	HB	HCC	Goldengate	53.8 ± 10.3	41.1 ± 10.3	242	482	18	100	124	41	195	246	0.789
Rosales 2016 [29]	Mexico	Latin	PB	CRC	PCR–RFLP	59.03 (mean)	36.88 (mean)	188	99	54	109	25	18	59	22	0.054
Bahl 2017 [30]	India	Asian	HB	LC	PCR–RFLP	57.38 ± 10.74	53.23 ± 10.44	303	305	54	150	99	80	144	81	0.330

1365 C/T										TT	TC	CC	TT	TC	CC
Bahl 2017 [30]	India	Asian	HB	LC	PCR–RFLP	57.38 ± 10.74	53.23 ± 10.44	303	305	6	29	268	5	51	249	0.215
Pinarbasi 2011 [27]	Turkey	Caucasian	HB	PC	PCR	70.38 ± 7.78	68.55 ± 4.47	84	100	0	7	77	0	8	92	0.677
Gunes 2010 [25]	Turkey	Caucasian	HB	AT	PCR	58.66 ± 8.039	57.01 ± 7.89	100	100	0	9	91	0	12	88	0.523
Gunes 2009 [19]	Turkey	Caucasian	PB	LC	PCR	59.22 ± 9.63	57.01 ± 7.89	100	100	0	9	91	0	12	88	0.523

rs4791171A/G										GG	GA	AA	GG	GA	AA
Alanazi 2013 [20]	Saudi	Arabian	HB	BC	RT-PCR	48.0 (mean)	NA	99	83	21	44	34	17	44	22	0.559
Yadav 2016 [23]	India	Asian	HB	GBC	PCR–RFLP	52.05 ± 10.06	43.2 ± 11.5	564	250	228	248	88	97	118	35	0.926
Parine 2019 [33]	Saudi	Arabian	HB	CRC	TaqMan	57.0 (mean)	NA	122	110	27	55	40	24	48	38	0.236

HB hospital-based, PB population-based, AT astrocytoma, BC breast cancer, CRC colorectal cancer, GBC gallbladder cancer, PCR–RFLP polymerase chain reaction and restrictive fragment length polymorphism, RT real time, NA not available, NOS Newcastle–Ottawa Scale, HCC hepatocellular carcinoma, HNC head and neck cancer, HWE Hardy–Weinberg equilibrium of controls, LC lung adenocarcinoma, PC prostate adenocarcinoma, PTC papillary thyroid carcinoma, OC ovarian cancer

ISSN: 1475-2867